PRTA
Prothena Corporation plc
NASDAQ · IEHealthcareBiotechnology
$8.67+0.12%
Price as of Jul 20, 2026
PRTA financials
Prothena Corporation plc financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $9.7M | $135.2M | $91.4M | $53.9M |
| Cost of revenue | $3.7M | $0.00 | $0.00 | $0.00 |
| Gross profit | $6.0M | $135.2M | $91.4M | $53.9M |
| Operating expenses | $190.5M | $289.7M | $282.4M | $185.5M |
| Operating income | -$184.6M | -$154.6M | -$191.0M | -$131.6M |
| Net income | -$244.1M | -$122.3M | -$147.0M | -$116.9M |
| EBITDA | -$197.1M | -$128.0M | -$159.6M | -$124.9M |
| Basic EPS | $-4.53 | $-2.27 | $-2.76 | $-2.47 |
| Diluted EPS | $-4.53 | $-2.27 | $-2.76 | $-2.47 |
| Balance sheet | ||||
| Cash & equivalents | $307.5M | $471.4M | $618.8M | $710.4M |
| Total assets | $326.8M | $547.1M | $696.4M | $758.0M |
| Total liabilities | $46.3M | $60.2M | $135.0M | $136.0M |
| Stockholders’ equity | $280.5M | $486.9M | $561.4M | $622.0M |
| Total debt | $13.9M | $10.8M | $11.8M | $6.5M |
| Net debt | -$293.7M | -$460.5M | -$607.0M | -$703.9M |
| Cash flow | ||||
| Operating cash flow | -$163.6M | -$150.1M | -$133.9M | -$108.8M |
| Capital expenditure | -$138.0K | -$298.0K | -$2.8M | -$464.0K |
| Free cash flow | -$163.7M | -$150.3M | -$136.7M | -$109.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | -$353.0K | $0.00 | $0.00 |